Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Xiao S, Peng Y, Peng L, Xie X, Qin J, Ma H, Kang X, Bing C, Huang B, Liang K, Zhao Y, Rong X, Feng X, Fan X, Ashktorab H, Zhang Z, Jin Z, Zhang X. The novel protein SEMA3C-319aa triggers glutathione metabolism-dependent ferroptosis in gastric cancer. Oncogene. 2025 Oct; 44(39):3679-3693.
-
Aare M, Padakanti SC, Singh M. In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts. AAPS PharmSciTech. 2025 Sep 11; 26(7):227.
-
Aare M, Lazarte JMS, Muthu M, Rishi AK, Singh M. Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer. Drug Deliv Transl Res. 2026 Feb; 16(2):693-710.
-
Daniels MH, Castro J, Lee YT, Gotur D, Knockenhauer KE, Grigoriu S, Lockbaum GJ, Cheong JE, Lu C, Brennan D, Buker SM, Liu J, Yao S, Sparling BA, Sickmier EA, Ribich S, Blakemore SJ, Silver SJ, Boriack-Sjodin PA, Duncan KW, Copeland RA. Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9. J Med Chem. 2025 May 08; 68(9):9537-9554.
-
Yi S, Noh K, Kim H, Jung E, Kim S, Lee J, Guk K, Choi J, Lim EK, Kim S, Park H, Lim JH, Jung CR, Kang T, Jung J. Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation. Mol Cancer. 2025 Apr 24; 24(1):124.
-
Rivera-Serrano M, Flores-Col?n M, Valiyeva F, Mel?ndez LM, Vivas-Mej?a PE. Upregulation of MMP3 Promotes Cisplatin Resistance in Ovarian Cancer. Int J Mol Sci. 2025 Apr 24; 26(9).
-
Li X, Mamouni K, Zhao R, Bai L, Chen Y, Wu Y, Xie ZR, Sautto GA, Liu D, Bowen NJ, Danaher A, Li D, Cook N, Grayson S, Zhu J, Coleman IM, Nelson PS, Bao Q, Zhou J, Osunkoya AO, Kucuk O, Gera L, Wu D. Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer. Br J Cancer. 2025 Jun; 132(12):1188-1199.
-
Nathani A, Sun L, Li Y, Lazarte J, Aare M, Singh M. Targeting EGFR-TKI resistance in lung cancer: Role of miR-5193/miR-149-5p loaded NK-EVs and Carboplatin combination. Int J Pharm. 2025 Apr 30; 675:125573.
-
Liu J, Shen Y, Liu J, Xu D, Chang CY, Wang J, Zhou J, Haffty BG, Zhang L, Bargonetti J, De S, Hu W, Feng Z. Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation. Nat Commun. 2025 Feb 19; 16(1):1762.
-
Castro J, Daniels MH, Brennan D, Johnston B, Gotur D, Lee YT, Knockenhauer KE, Lu C, Wu J, Nayak S, Collins C, Bansal R, Buker SM, Case A, Liu J, Yao S, Sparling BA, Sickmier EA, Silver SJ, Blakemore SJ, Boriack-Sjodin PA, Duncan KW, Ribich S, Copeland RA. A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. Cancer Res. 2025 Feb 17; 85(4):758-776.